Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Honoraria | $3,000 | 6 | 91.8% |
| Food and Beverage | $268.33 | 13 | 8.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Athenex Pharmaceutical Division, LLC | $3,022 | 7 | $0 (2021) |
| Incyte Corporation | $100.00 | 1 | $0 (2018) |
| Merck Sharp & Dohme Corporation | $42.13 | 3 | $0 (2020) |
| Celgene Corporation | $36.78 | 2 | $0 (2018) |
| Exelixis Inc. | $16.12 | 1 | $0 (2017) |
| TerSera Therapeutics LLC | $15.40 | 1 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $12.74 | 1 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $10.65 | 1 | $0 (2017) |
| Relypsa, Inc. | $10.46 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $500.00 | 1 | Athenex Pharmaceutical Division, LLC ($500.00) |
| 2020 | $2,014 | 5 | Athenex Pharmaceutical Division, LLC ($2,000) |
| 2019 | $548.85 | 4 | Athenex Pharmaceutical Division, LLC ($521.72) |
| 2018 | $136.78 | 3 | Incyte Corporation ($100.00) |
| 2017 | $68.65 | 6 | Merck Sharp & Dohme Corporation ($16.35) |
All Payment Transactions
19 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/11/2021 | Athenex Pharmaceutical Division, LLC | — | Honoraria | Cash or cash equivalent | $500.00 | General |
| 09/24/2020 | Athenex Pharmaceutical Division, LLC | Oral Paclitaxel (Drug), Encequidar | Honoraria | Cash or cash equivalent | $500.00 | General |
| Category: Metastatic Breast Cancer | ||||||
| 07/09/2020 | Athenex Pharmaceutical Division, LLC | Oral Paclitaxel (Drug), Encequidar | Honoraria | Cash or cash equivalent | $500.00 | General |
| Category: Metastatic Breast Cancer | ||||||
| 06/05/2020 | Athenex Pharmaceutical Division, LLC | Oral Paclitaxel (Drug), Encequidar | Honoraria | Cash or cash equivalent | $500.00 | General |
| Category: Metastatic Breast Cancer | ||||||
| 02/03/2020 | Athenex Pharmaceutical Division, LLC | Oral Paclitaxel (Drug), Encequidar | Honoraria | Cash or cash equivalent | $500.00 | General |
| Category: Metastatic Breast Cancer | ||||||
| 01/24/2020 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological), LENVIMA | Food and Beverage | In-kind items and services | $14.05 | General |
| Category: ONCOLOGY | ||||||
| 07/11/2019 | Athenex Pharmaceutical Division, LLC | Oral Paclitaxel (Drug), Encequidar | Honoraria | Cash or cash equivalent | $500.00 | General |
| Category: Metastatic Breast Cancer | ||||||
| 07/03/2019 | Athenex Pharmaceutical Division, LLC | Oral Paclitaxel (Drug), Encequidar | Food and Beverage | In-kind items and services | $21.72 | General |
| Category: Metastatic Breast Cancer | ||||||
| 05/24/2019 | TerSera Therapeutics LLC | ZOLADEX (Drug) | Food and Beverage | In-kind items and services | $15.40 | General |
| Category: ONCOLOGY | ||||||
| 04/05/2019 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological), LENVIMA | Food and Beverage | In-kind items and services | $11.73 | General |
| Category: ONCOLOGY | ||||||
| 12/28/2018 | Celgene Corporation | Abraxane (Drug) | Food and Beverage | In-kind items and services | $19.07 | General |
| Category: Oncology | ||||||
| 04/11/2018 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $100.00 | General |
| Category: Hematology/Oncology | ||||||
| 01/15/2018 | Celgene Corporation | Revlimid (Drug) | Food and Beverage | In-kind items and services | $17.71 | General |
| Category: Hematology / Oncology | ||||||
| 11/27/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $12.74 | General |
| Category: Oncology | ||||||
| 11/10/2017 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $16.35 | General |
| Category: ONCOLOGY | ||||||
| 09/01/2017 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug), TAFINLAR | Food and Beverage | In-kind items and services | $10.65 | General |
| Category: ONCOLOGY | ||||||
| 07/11/2017 | Exelixis Inc. | Cabometyx (Drug) | Food and Beverage | In-kind items and services | $16.12 | General |
| Category: Oncology | ||||||
| 06/04/2017 | PFIZER INC. | BAVENCIO (Drug) | Food and Beverage | In-kind items and services | $2.33 | General |
| Category: ONCOLOGY | ||||||
| 05/23/2017 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $10.46 | General |
| Category: Hyperkalemia | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2020 | 2 | 51 | 51 | $7,449 | $1,085 |
All Medicare Procedures & Services
2 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 27 | 27 | $4,650 | $901.35 | 19.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 24 | 24 | $2,799 | $183.85 | 6.6% |
About Dr. Alan Lyss, MD
Dr. Alan Lyss, MD is a Hematology & Oncology healthcare provider based in Saint Louis, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1013920651.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alan Lyss, MD has received a total of $3,268 in payments from pharmaceutical and medical device companies, with $500.00 received in 2021. These payments were reported across 19 transactions from 10 companies. The most common payment nature is "Honoraria" ($3,000).
As a Medicare-enrolled provider, Lyss has provided services to 51 Medicare beneficiaries, totaling 51 services with total Medicare billing of $1,085. Data is available for 1 year (2020–2020), covering 2 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Location Saint Louis, MO
- Active Since 08/14/2006
- Last Updated 12/06/2007
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1013920651
Products in Payments
- Oral Paclitaxel (Drug) $2,522
- JAKAFI (Drug) $100.00
- KEYTRUDA (Biological) $42.13
- Abraxane (Drug) $19.07
- Revlimid (Drug) $17.71
- Cabometyx (Drug) $16.12
- ZOLADEX (Drug) $15.40
- OPDIVO (Biological) $12.74
- MEKINIST (Drug) $10.65
- Veltassa (Drug) $10.46
- BAVENCIO (Drug) $2.33
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Saint Louis
Maurice Willis, Md, MD
Hematology & Oncology — Payments: $77,431
Dr. Geoffrey Uy, Md, MD
Hematology & Oncology — Payments: $29,892
Dr. Jason Li, Md, MD
Hematology & Oncology — Payments: $22,919
John Finnie, Md, MD
Hematology & Oncology — Payments: $17,276
Dr. Atif Shafqat, M.d, M.D
Hematology & Oncology — Payments: $13,313
Dr. Shabbir Safdar, M.d, M.D
Hematology & Oncology — Payments: $12,290